N6-Propyl-4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine Dihydrochloride Hydrate

The reference material cataloged as N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride hydrate (CAS 191217-81-9) corresponds to the monohydrate form of pramipexole dihydrochloride, a non‑ergot dopamine agonist. Its molecular formula is C₁₀H₁₇N₃S·2HCl·H₂O with a formula weight of 302.26 g·mol⁻¹. The substance is supplied as a white to off‑white crystalline powder and serves as a primary pharmacopeial reference standard for identity, assay, and purity tests under the USP Pramipexole Dihydrochloride monograph and the corresponding Ph. Eur. monograph 01/2023:2747. A single batch of this hydrate typically exhibits an HPLC purity of ≥99.8% (area‑% at 262 nm), with individual specified impurities limited to ≤0.10% and total impurities ≤0.5%. Because the hydrate stoichiometry directly impacts the assay value used to calculate the content of pramipexole base in pharmaceutical formulations, this specific hydration state is mandatory for official monograph applications; the anhydrous form or free base cannot be substituted without recalibration of response factors.

Stability Under Forced Degradation Conditions

When stressed according to ICH Q1A(R2) guidelines, the dihydrochloride hydrate shows distinct degradation profiles that are critical to analytical method specificity. Thermolytic stress at 105 °C for 24 hours primarily yields the de‑propylated analogue (4,5,6,7‑tetrahydro‑1,3‑benzothiazole‑2,6‑diamine), which elutes with a relative retention time (RRT) of approximately 0.45 on a C18 column (150 × 4.6 mm, 5 µm) under the isocratic mobile phase described in the USP procedure (phosphate buffer pH 3.0 / acetonitrile 85:15 v/v). Oxidative stress with 3% hydrogen peroxide at ambient temperature for 4 hours generates two additional degradation products with RRTs of 0.72 and 1.28, the latter being the N‑oxide derivative. Photolytic exposure per ICH Q1B Option 2 (visible light 1.2 million lux·hours, UV 200 W·h·m⁻²) does not significantly alter purity, provided the powder is stored in amber glass. These forced‑degradation outcomes are reproducible only when the hydrate form is used; the anhydrous dihydrochloride displays a different oxidative susceptibility due to lattice‑water‑mediated stabilization of the protonated amino groups. Purity verification after stress testing is performed against a frozen, un‑stressed retain sample of the same lot to avoid inter‑lot variability.

What Distinguishes This Hydrate from the Anhydrous Free Base?

A direct gravimetric substitution of the free base for the dihydrochloride hydrate is not possible because of fundamental differences in physical properties and analytical response. The free base (pramipexole, CAS 104632-26-0) is a lipophilic solid with an aqueous solubility below 2 mg·mL⁻¹ at 25 °C and a melting point of 127–130 °C. In contrast, the dihydrochloride monohydrate dissolves at ≥200 mg·mL⁻¹ in water, and its melting event is accompanied by decomposition at 296–298 °C. The chromatographic retention differs as well: under the official USP system, the free base elutes approximately 0.25 minutes later than the dihydrochloride due to the absence of ion‑pair interaction with the residual silanols on the C18 stationary phase. For quantitative NMR applications, the chemical shift of the C‑6 methine proton moves from 3.52 ppm (free base in DMSO‑d₆) to 3.71 ppm (dihydrochloride hydrate in D₂O). Importantly, the specific optical rotation of the dihydrochloride monohydrate, measured at 20 °C in methanol at a concentration of 10 mg·mL⁻¹, falls within the range of −67° to −73° (sodium D‑line 589 nm), whereas the free base shows a rotation of approximately −93° to −99° under identical conditions. Any reference material lot failing to meet the optical rotation specification for the hydrate is rejected as a mis‑identified form.

Moisture sorption behavior creates another operational boundary. Dynamic vapor sorption (DVS) analysis at 25 °C shows that the monohydrate is stable between 10% and 70% relative humidity, with mass variation below 0.15%. At RH ≥80%, the material uptakes an additional 0.5–0.8% water, forming a metastable higher hydrate, while at RH ≤5% it gradually loses lattice water, converting to the anhydrous dihydrochloride over 48 hours. These transitions are fully reversible, but they alter the HPLC area‑% response per unit mass. Therefore, handling protocols require equilibration at 20–25 °C and 40–60% RH for at least 4 hours before weighing, with Karl Fischer water determination run on each day of use. The product specification limits water content to 5.5–6.1% w/w (theory for monohydrate: 5.96%).

When Pharmacopeial Monograph Compliance Requires Dihydrochloride Hydrate

The USP monograph for Pramipexole Dihydrochloride specifies system suitability criteria that can only be met with the hydrate reference standard. Resolution between pramipexole and the S‑enantiomer (CAS 104632-27-1) must be not less than 2.0, and the tailing factor for the pramipexole peak must not exceed 2.0. These parameters are verified on a C18 column (250 × 4.6 mm, 5 µm) with a mobile phase of sodium phosphate monobasic buffer (0.05 M, pH 3.0) and acetonitrile (85:15) at 1.0 mL·min⁻¹, column temperature 30 °C, and detection at 262 nm. The resolution requirement drives the choice of the dihydrochloride over the monohydrochloride because the monohydrochloride exhibits a broader peak in this system (tailing factor typically 2.2–2.5), attributable to ion‑pair disruption during the injection onto a silica‑based stationary phase. In pharmaceutical quality control environments following 21 CFR 211.194(a), the use of an official reference standard—or a secondary standard traceable to it via collaborative assay—is mandated for method implementation. The dihydrochloride hydrate described here fulfills that role directly, and its certificate of analysis provides traceability to the USP reference standard lot.

A direct application of the reference material is calibration of the liquid chromatograph for assay determination in tablets containing 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, or 1.5 mg of pramipexole dihydrochloride monohydrate. Standard solutions at 0.5 mg·mL⁻¹ in the dissolution medium (0.01 N HCl) are stable for 7 days at 5 °C, but analyte adsorption onto borosilicate glass surfaces necessitates the use of polypropylene volumetric ware when concentrations fall below 10 µg·mL⁻¹. This container‑analyte interaction is not observed with the free base or the monohydrochloride, owing to the higher ionic strength contributed by the dihydrochloride in solution; thus, a method validated specifically for the dihydrochloride hydrate cannot be directly transferred to other salt forms without a container‑compatibility reassessment.

Using Quantitative NMR to Bypass Reference Standard Limitations

When a pharmacopeial reference lot is unavailable or has been exhausted, absolute purity can be assigned to a batch of dihydrochloride hydrate via ¹H‑qNMR using an internal certified reference standard such as maleic acid (CRM NIST SRM 350b). The method exploits the well‑resolved doublet of the benzylic proton at C‑7 (~3.15 ppm) and the singlet of the thiazole proton at C‑9 (~6.58 ppm) in D₂O. A typical acquisition on a 500 MHz spectrometer uses a 30° pulse, a relaxation delay of 60 s (>5 × T₁), 64 scans, and a spectral width of 12 ppm. Under these conditions, the limit of quantitation for total impurities is 0.1%. A mass‑balance approach combining qNMR purity, water content by Karl Fischer, residual solvents by headspace GC‑FID (validated for methanol, ethanol, isopropanol, and acetonitrile per USP <467>), and residue on ignition yields an assay value with an expanded uncertainty (k=2) of ±0.4%. This independent route confirms that the dihydrochloride hydrate lot is suitable as a working standard even in the absence of a currently active official reference lot. The qNMR approach is less precise for the free base because of solubility limitations in D₂O, so the hydrate remains the preferred form for reference standard certification.

The following table captures the critical quality attributes and their acceptance criteria used in batch release, reflecting the combined pharmacopeial and qNMR orthogonal approach.

A second table directly compares the key handling and performance characteristics of the three commercially available pramipexole chemical forms, underscoring why the dihydrochloride hydrate is specified in official monographs.

In production environments, the dihydrochloride hydrate is the form loaded into dry‑mix formulations for immediate‑release tablets via direct compression. Pre‑blending with silicified microcrystalline cellulose (Prosolv HD 90) at a 1:5 ratio in a V‑blender (25 L working volume, 25 rpm, 15 minutes) achieves content uniformity with a relative standard deviation of ≤2.0%, a result not achievable with the free base because of its electrostatic charging and poor flow. The hydrate’s particle size is controlled through jet‑milling to a D₉₀ of ≤30 µm; tighter milling to D₉₀ ≤10 µm is avoided because of hydrate breakdown during micronization, evidenced by an endotherm shift in modulated DSC. Published data for this specific hydration‑sensitivity in micronization is limited, but batch‑to‑batch audit trails show that out‑of‑specification water content correlates with over‑milling events.